The investment will be used to advance StemSight toward clinical trials for limbal stem cell deficiency (LSCD), a specific type of corneal blindness.

“This funding shows that they believe in our vision for StemSight and the world-class team we have put together to bring that vision to life. We are working on the cutting edge of regenerative medicine, and we are eager to push science to new frontiers,” says Laura Koivusalo, CEO and Founder at StemSight.

The funding will enable key preclinical studies, R&D expansion, and manufacturing pilots, advancing StemSight toward clinical trials and bringing new hope to patients with incurable corneal blindness, the company states.

Product StemSight

“StemSight’s innovative approach to regenerative medicine stands out for us in the biotech space. By addressing severe corneal blindness through the use of emerging stem cell therapies, they are bringing hope to patients who have no existing treatment options. StemSight’s work on LSCD is just the start – this technology has the potential to transform vision care globally. We are proud to continue supporting their journey in pioneering solutions for patients worldwide,” says Stina Wallmark, Life Sciences Investment Director at Voima Ventures.

Team StemSight